express only the gag and pol genes of MLV (293gp/bsr [N. V. Somia and I. M. Verma, unpublished data] ). This cell line was used to generate a virus that transduces the gene for green fluorescent protein (GFP) on transfection of a retroviral vector, pCLMFG-GFP (24) . Another cell line that further expresses the transcript for the retroviral vector pCLMFG-lacZ (293gp/lacZ [Somia and Verma, unpublished data]) was used to generate a virus that transduces the gene for ␤-galactosidase (␤-Gal). CD4, CXCR4, and CCR5 expression constructs (singly or in combinations) or an expression plasmid for the amphotropic env were transfected as indicated below to substitute for the envelope.
We first determined the expression of the amphotropic envelope, CD4, and CXCR4 in the 293gp/lacZ cells, and their relative levels of incorporation into viral particles, by immunoblot analysis. Figure 2A shows the efficiency of incorporation of the amphotropic envelope into viral particles. It further shows that CD4 can be incorporated into viral particles, though not as efficiently as the amphotropic envelope. This extends to MLV the observations regarding CD4 incorporation into ALV. Since envelopes of retroviruses are not necessarily interchangeable, pseudotyping of other molecules needs to be tested empirically. Finally, CXCR4 is incorporated, but at a very low level compared to the amphotropic envelope and CD4. The Gag polyprotein in the cell pellet and the processed FIG. 1. Schematic illustration for the experimental approach described in the text. Infection by HIV is mediated by gp120 binding to CD4 and a coreceptor (CXCR4 for T-cell-tropic envelopes or CCR5 for macrophage-tropic envelopes). During the life cycle of HIV, gp120 is expressed on the cell surface, and so a Moloney MLV-based retroviral vector, displaying CD4 and a coreceptor, was generated to test if it was specific for infection of gp120-expressing cells. (21) , CD4 (CMX-CD4, a gift from Didier Trono), or CXCR4 (pc.Fusin) (9) were transfected into 5 ϫ 10 5 293gp/ lacZ cells, according to the method of Chen and Okayama (4). Mocktransfected cells (Ϫ) were similarly treated, but no plasmid was transfected. After overnight incubation, the medium was changed, and the vector was harvested 48 h later. The cells were collected and lysed in 1 ml of lysis buffer (20 mM Tris-HCl [pH 8.0], 1 mM CaCl 2 , 150 mM NaCl, 1% Triton), and the cell extract (1 l for the amphotropic envelope, CD4, and loading controls; 10 l for CXCR4) was transferred to a nitrocellulose membrane for immunoblot analysis. The supernatant was filtered through a 0.45-m-pore-size filter, the viral particles were pelleted through a 20% sucrose cushion by ultracentrifugation (90,000 ϫ g for 1.5 h) and resuspended in 1 ml of lysis buffer, and the viral extract (1 l for the amphotropic envelope, CD4, and loading controls; 10 l for CXCR4) was transferred to a nitrocellulose membrane for immunoblot analysis. Primary (1°) antibodies used were goat anti-Raushers gp69/71 (National Cancer Institute/Biological Carcinogenesis Branch repository) (␣-env), rabbit anti-human CD4 (8) p30 protein in the viral pellets provide loading controls. The relative level of incorporation of CXCR4 into the viral particle is much lower than that of CD4.
To test if expression of CD4 and CXCR4 in 293gp/lacZ cells produced a vector capable of infecting gp120-expressing cells, we utilized a cell line, 69T1RevEnv (31) , which conditionally expresses T-cell-tropic gp120 by placing the HIV-1 env gene under the control of a tetracycline-responsive promoter (16) . Expression of gp120 is repressed by the presence of tetracycline or its analogue doxycycline (Dox). Figure 2B shows an immunoblot analysis for gp120 expression in 69T1RevEnv cells in the presence or absence of Dox. The expression of gp120 was detected only in the absence of Dox (Fig. 2B, lane 4) . MLV vectors were produced by the transfection of various expression constructs into 293gp/lacZ cells and were used to infect 69T1RevEnv cells with and without the addition of Dox. Table  1 illustrates that infection was contingent upon gp120 expression and was observed only when both CD4 and CXCR4 are used to generate the vectors, with an average titer of 2.6 ϫ 10 3 /ml. Dox had no adverse effect on viral infection, since the amphotropic envelope (using a phosphate transporter as a receptor) (23) enabled infection with equal efficiencies in the absence and presence of Dox. Table 1 also illustrates that the viral vector can be quantitatively concentrated 100-fold by ultracentrifugation. The infection is specific for the tropism of the gp120 moiety, since the CCR5-pseudotyped vector did not mediate infection. The fact that the CCR5 molecule is functional and incorporated into the vector is illustrated in Fig. 2C , where transduction by a vector pseudotyped with CCR5 and CD4 is shown on 293 cells expressing a macrophage-tropic gp120 molecule. In this case, pseudotyping CXCR4 and CD4 did not result in transduction. It is interesting that CD4 expression alone was unable to produce a vector capable of infecting gp120-and gp41-expressing cells, even though the 69T1RevEnv cells express endogenous CXCR4. This suggests that both CD4 and CXCR4 are required on the same face for infection to be productive, and this stero-restriction is consistent with the recently defined structure of the gp120-CD4 complex (20) .
We next tested the ability of the CD4-and CXCR4-pseudotyped MLV vector to infect cells that have been productively infected with wild-type HIV-1. To this end we utilized a cell line, HeLa CD4-LTR/␤-gal, that was constructed by Kimpton and Emerman (18) . This is a HeLa cell line that has been engineered to ectopically express CD4. Since this cell line already expresses endogenous CXCR4, it can be infected with T-cell-tropic HIV-1 (HIV-1 IIIB). Kimpton and Emerman further manipulated these cells so that they harbor an Escherichia coli ␤-Gal reporter gene under the control of the HIV-1 LTR. HIV-1 infection of HeLa CD4-LTR/␤-gal cells results in the production of the transactivator Tat, which in turn activates expression of the ␤-Gal gene. Hence, expression of ␤-Gal is an indicator of infection by HIV-1. HeLa CD4-LTR/␤-gal cells were infected with HIV-1 IIIB. Figure 2B indicates that these infected cells express significant amounts of gp120 (Fig. 2B,  lane 2) , which comigrates with gp120 from T cells infected with HIV-1 IIIB (Fig. 2B, lane 6) (13) . The CD4-and CXCR4-pseudotyped vector containing the GFP gene was used to infect HIV-infected HeLa CD4-LTR/␤-gal cells. Figure 3 shows that infection by this vector was observed only in HIV-1-infected cells, since only cells infected with HIV-1 (blue, ␤-Galpositive cells) were also found to express GFP. A vector with an amphotropic envelope transduced both HIV-1-infected and uninfected cells, since GFP expression was found in both ␤-Gal-positive and -negative cells. The titer was 10 2 /ml, which is 1 log lower than that observed on 69T1RevEnv cells; however, only a proportion of the HeLa CD4-LTR/␤-gal cells were infected with HIV-1, as shown by the number of blue, ␤-Galpositive cells in Fig. 3 .
We have demonstrated above that MLV-based vectors can be pseudotyped with CD4 and CXCR4, directing infection to cells expressing T-cell-tropic HIV-1 env. Other groups have reported targeting to gp120-expressing cells. Endres et al. (11) have shown incorporation of CD4 and CCR5 or CXCR4 into an HIV-1-based vector with titers of 10 4 /ml. This vector can be used to transduce HIV-1-infected cells, though the vector will be remobilized with a gp120 envelope-based tropism. This can lead to an overestimation of the titer and may also limit the types of molecules that could be transduced to HIV-1-infected cells in vivo, since a remobilized vector may infect a CD4 cell that has not been infected with HIV-1. This may limit the transgene in the vector to nontoxic molecules. Furthermore, this may seem an attractive approach in some cases because the HIV-1-based vector is amplified in vivo in proportion to the number of HIV-1-infected cells; however, it is limited as a treatment, since concomitant therapies that interfere with HIV-1 replication would also affect vector production. Mebatsion et al. (22) MLV-based vectors provide an alternative way to target HIV-1-infected cells without remobilizing them or causing lysis. This method can also be used in conjunction with most other anti-HIV therapies. The vectors may be used to deliver genes coding for antigenic molecules that upregulate the immune response against HIV-1-infected cells. However, the titer needs to be drastically improved for any efficacious therapeutic applications. Indeed, the total number of HIV-1 particles produced in an infected patient has been estimated at 10 9 per day (17, 28) . Clearly, one means of achieving a higher titer is to increase the level of incorporation of CXCR4-possibly by making CXCR4 chimeric molecules that retain CD4 ϩ CXCR4 (ϫ100) Ͻ10 4.9 ϫ 10 5 a 293gp/lacZ cells were transfected (4) with 10 g of CMX-CD4, 15 g of pc.Fusin (CXCR4), or 15 g of pcCCR5 or the combinations indicated. The total DNA was kept constant at 25 g by the addition of a carrier plasmid pEGFP (Clontech). Vectors were harvested as described in the legend for Fig. 1 , and 1 ml of medium was used to infect 5 ϫ 10 4 69T1RevEnv cells overnight in the presence (1 g/ml) or absence of Dox. One hundred microliters was used in the case of the amphotropic envelope. The infection was carried out in a total volume of 2 ml of medium. The medium was changed 48 h later, and the cells were stained for ␤-Gal expression (25) with 5-bromo-4-chloro-3-indolyl-␤-Dgalactopyranoside. Concentrated virus was prepared by ultracentrifugation of the supernatant (40 ml) at 50,000 ϫ g and resuspension in 400 l of cell culture medium. Viral suspension (100 l) was used for infection of 69T1RevEnv cells, and the titer was determined according to the number of cells expressing ␤-Gal. The values are the means of the results from two independent experiments. gp120 binding but facilitate higher levels of expression and incorporation into viral particles. In this regard, CXCR4 and CD4 fusions (19) may be of interest.
The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: clone 69T1RevEnv from Joseph Dougherty, HeLa-CD4-LTR/␤-gal from Michael Emerman, antiserum to CD4 (T4-4) from R. Sweet (SmithKline Beecham Pharmaceuticals), antiserum to HIV-1 gp120 from Michael Phelan, and pc.Fusin, pcCCR-5, and pSV-JRFL-env from Nathaniel Landau. We thank Didier Trono for the CMX-CD4 expression plasmid and the Molt-IIB cells. We are also grateful to Edward Berger for the gift of the 4G10 anti-CXCR4 monoclonal antibody.
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